Should I buy or sell NeurAxis stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeurAxis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NRXS shares. View NRXS analyst ratings or view top-rated stocks .

How have NRXS shares performed in 2023?

NeurAxis' stock was trading at $6.00 at the beginning of 2023. Since then, NRXS stock has decreased by 45.7% and is now trading at $3.26. View the best growth stocks for 2023 here .

How were NeurAxis' earnings last quarter?

NeurAxis, Inc. (NASDAQ:NRXS) issued its earnings results on Thursday, September, 21st. The company reported ($1.21) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.99. The business had revenue of $0.65 million for the quarter.

When did NeurAxis IPO?

(NRXS) raised $7 million in an initial public offering on Wednesday, August 9th 2023. The company issued 1,098,667 shares at a price of $6.00 per share.

Who are NeurAxis' major shareholders?

NeurAxis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Stifel Financial Corp (0.52%).

How do I buy shares of NeurAxis?

Shares of NRXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

NeurAxis Stock Price, News & Analysis (NASDAQ:NRXS)

$3.26

+0.26 (+8.67%)

(As of 11/29/2023 ET)

Compare

Today's Range: $2.25
▼
$3.36
50-Day Range: $1.90
▼
$4.18
52-Week Range: $1.80
▼
$6.93

Volume: 49,470 shs
Average Volume: 40,835 shs
Market Capitalization: $17.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About NeurAxis Stock (NASDAQ:NRXS)

NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

NRXS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NRXS Stock News Headlines

November 21, 2023 | finanznachrichten.de

NeurAxis, Inc.: NeurAxis Reports Third Quarter 2023 Financial Results

November 21, 2023 | msn.com

NeurAxis reports Q3 results

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 20, 2023 | finance.yahoo.com

NeurAxis Reports Third Quarter 2023 Financial Results

November 15, 2023 | finance.yahoo.com

NeurAxis Announces CareFirst BCBS Policy Coverage

November 14, 2023 | msn.com

NeurAxis secures $3M financing through preferred stock offering

November 14, 2023 | finance.yahoo.com

NeurAxis Secures $3 Million Financing

November 8, 2023 | finance.yahoo.com

NeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 5, 2023 | morningstar.com

Neuraxis Inc NRXS Stock Quote

September 26, 2023 | finance.yahoo.com

NeurAxis Announces Results of Comparative Study of IB-Stim™ and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders

September 21, 2023 | finance.yahoo.com

NeurAxis Reports Second Quarter 2023 Financial Results

September 13, 2023 | finance.yahoo.com

NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase

September 12, 2023 | stockhouse.com

NeurAxis Announces Publication of Prospective Study Showing IB-Stim(TM) Improves Quality of Life of Adolescents with IBS

September 12, 2023 | msn.com

EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome

September 12, 2023 | finance.yahoo.com

NeurAxis Announces Publication of Prospective Study Showing IB-Stim™ Improves Quality of Life of Adolescents with IBS